Last reviewed · How we verify
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
Details
| Lead sponsor | H. Lundbeck A/S |
|---|---|
| Phase | PHASE2 |
| Status | TERMINATED |
| Enrolment | 168 |
| Start date | Thu Dec 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Sep 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Schizophrenia
Interventions
- Lu AF11167 (1-2 mg/day)
- Lu AF11167 (3-4 mg/day)
- Placebo
Countries
Ukraine, Estonia, Germany, Hungary, Poland, Bulgaria, Latvia, Czechia